Rising Players Influencing the Skin Disorders Industry
The dermatology market is expanding due to growing demand. The pharmaceutical industry is experiencing a significant transformation, with numerous startups entering the market for dermatological products. As skin disorders continue to rise, the dermatology sector has become one of the fastest-growing therapeutic areas. Notably, the substantial growth in dermatology not only underscores its vital role in treating various skin conditions but also reflects increasing consumer awareness and emphasis on dermatological care. Below are a few emerging players in the dermatology market:
1. Almirall
Almirall is a global pharmaceutical company focused on medical dermatology. With a strong foundation in scientific understanding of skin diseases, Almirall aims to deliver impactful treatments that transform lives. Their commitment to innovation and long-term contributions to the dermatology community makes them a valued player in the field. The company also invests in research, education, and advocacy to raise awareness of dermatological conditions. In the 1H 2024, Almirall reported a 6.7% increase in net sales, reaching €497.2 million, driven by growth in its European Dermatology business and biologics. Core net sales grew 5.1% to €436.6 million, with EBITDA of €104.5 million (+3.2% YoY). Key growth drivers include the successful launch of Ebglyss® in Germany and strong sales of Ilumetri®, which saw a 25% increase compared to H1 2023. Other products like Wynzora® and Klisyri® also showed solid performance. The recent FDA approval of Klisyri for large field applications opens further growth opportunities.
Table 11- Pipeline analysis of dermatology drugs for Almirall
2. Alphyn Biologics
Alphyn Biologics is developing breakthrough therapies to treat the world's most challenging, severe, and common skin diseases. Alphyn has developed zabalafin hydrogel to be the first complete treatment for atopic dermatitis (AD), the most common form of eczema. With multiple bioactive components, zabalafin hydrogel is expected to directly attack and eliminate the itch, bacteria component and inflammation component of AD by directly targeting the bacteria living on the AD skin that discharge toxins that make AD symptoms worse and often cause infection and prevent healing. Zabalafin hydrogel is a non-steroidal, topical AD treatment, which is preferred by patients. It is targeted to offer patients and physicians a complete treatment for AD without the safety concerns of long-standing and new or experimental therapies. Zabalafin hydrogel’s safety, side effect and patient tolerability profile suggests it may be the first AD topical drug that can be used worry-free, long-term, and continuously. AD is a chronic disease that affects 10% percent of the population worldwide or some 800 million people globally. Its symptoms vary by individual but often include short or prolonged periods of severe inflammation, itchiness, rashes, scaly patches, blisters, and skin infections that cover small-to-large portions of the body.
Table 12- Pipeline analysis of dermatology drugs for Alphyn Biologics
3. Dermaliq Therapeutics, Inc.
Dermaliq Therapeutics, Inc. is a dermatology and aesthetics company with a robust pipeline focused on follicular diseases and conditions. The company is developing innovative medical aesthetics, self-pay prescription, and OTC products. Dermaliq's mission is to create a new generation of high-quality, user-friendly products that maximize efficacy and safety. Its proprietary “hyliQ®” technology addresses the “delivery barrier,” allowing for the absorption of multiple active ingredients and drugs directly into the follicle and skin, paving the way for “first in class” and “best in class” treatment options.
Table 13- Pipeline analysis of dermatology drugs for Dermaliq Therapeutics
4. Crescita Therapeutics
Crescita Therapeutics is a commercial dermatology company offering a range of prescription and over-the-counter products for the treatment and care of skin conditions, diseases, and their symptoms. In 2023, the company generated market revenue of $12.4 million. For Q2 2024, revenue was $4,088, down from $5,162 in Q2 2023.
Table 14- Pipeline analysis of dermatology drugs for Crescita Therapeutics
5. Carocell Bio
Carocell Bio is transforming the treatment of inflammatory diseases with its next-generation anti-inflammatory peptides, aimed at promoting healthier skin and healing. The company's pipeline of topically applied products is designed to disrupt the inflammatory cascade, offering potentially safer and more innovative therapeutic options for patients. This includes treatments for managing and preventing atopic dermatitis (eczema) and slowing the signs of skin aging.
Table 15- Pipeline analysis of dermatology drugs for Carocell Bio
6. Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company specializing in the development of therapies for both medical and aesthetic dermatology. Led by dermatologists, the company targets underserved markets with unmet medical needs or significant treatment gaps. Aclaris is dedicated to translating scientific discoveries into practical, everyday treatments for immuno-inflammatory conditions.
Table 16- Pipeline analysis of dermatology drugs for Aclaris Therapeutics